Other four patients developed active TB in a median of 21.4 months (IQR, 10.6–22.5 months) after the initiation of anti-TNF therapy, including two TST+QFT− patients who developed TB 22.0 or 20.8 months after anti-TNF therapy. The gene discussed is TNF; the disease is tuberculosis.